Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Blueprint Medicines

Rare disease drugmaker · part of Sanofi · based in Cambridge, United States · founded 2011 · blueprintmedicines.com

Blueprint Medicines works on 3 rare diseases we track, including Gastrointestinal Stromal Tumor, Mastocytosis and 1 more. It has 7 active clinical trials, and 6 are looking for volunteers now. It also has 1 FDA-approved rare disease drug.

Blueprint Medicines is a precision therapy company focused on genomically defined cancers and blood disorders. Sanofi completed its $9.1 billion acquisition of Blueprint on July 18, 2025 (announced June 2025). The lead product is avapritinib (Ayvakit/Ayvakyt), approved for advanced systemic mastocytosis, indolent systemic mastocytosis (ISM, approved 2023), and PDGFRA D842V-mutant gastrointestinal stromal tumors.

Blueprint Medicines pipeline

Each row lists the diseases Blueprint Medicines is studying at that stage, from the ones closest to approval down to the earliest work.

Approved
Drugs the FDA has approved.
Phase 3
Large studies, usually the last step before a company asks the FDA for approval.
Phase 2
Mid-size studies that check whether a drug works and at what dose.
Phase 1
First studies in people, mostly checking safety.
After approval
Studies that follow people already taking an approved drug.

Mastocytosis recruiting

Other studies
Studies with no phase listed, such as registries and natural history studies.

Systemic Mastocytosis 2 trials recruiting · Mastocytosis recruiting

Blueprint Medicines clinical trials

These are Blueprint Medicines trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.

6 trials looking for volunteers now

Looking for volunteersRecently updatedNCT07143669

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Tests Screening

For Clonal Mast Cell Disease, KIT D816V Mutation and Suspected KITD816V Mutated Clonal Mast Cell Disease

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Ages 18 Years+27 locations
View full study
Looking for volunteersPhase 4Recently updatedNCT06748001

Avapritinib Rollover Study

Tests Avapritinib

For Mastocytosis, Systemic

The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Ages not specified10 locations
View full study
Looking for volunteersRecently updatedNCT07255638

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Tests Avapritinib

For Indolent Systemic Mastocytosis

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.

Ages 18 Years+12 locations
View full study
Looking for volunteersPhase 2/3Recently updatedNCT04910685

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Tests Elenestinib, Placebo

For Indolent Systemic Mastocytosis and Smoldering Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.

Ages 18 Years+88 locations
View full study
Looking for volunteersRecently updatedNCT07264959

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

For Indolent Systemic Mastocytosis

This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.

Ages 18 Years+7 locations
View full study
Looking for volunteersPhase 1No updates in a whileNCT06327685

Avapritinib With Decitabine in Patients With SM-AHN

Tests Avapritinib, Decitabine, Decitabine/Cedazuridine

For Systemic Mastocytosis With an Associated Hematologic Neoplasm

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.

Ages 18 Years+7 locations
View full study

1 trial underway, not taking new volunteers

Underway, not taking new volunteersPhase 2Recently updatedNCT03731260

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Tests Avapritinib, Placebo

For Indolent Systemic Mastocytosis

This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.

Ages 18 Years+49 locations
View full study
Ask about Blueprint Medicines's trials
Answers with sources, in plain English
Start withor ask
Follow a condition Blueprint Medicines is studying

Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Blueprint Medicines. Unsubscribe anytime.

You'll get, for Gastrointestinal Stromal Tumor:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

FDA-approved drugs from Blueprint Medicines

From the openFDA database. Tap a drug for side effects, dosing and help paying.

Ayvakit avapritinib

For Gastrointestinal Stromal Tumor and Systemic Mastocytosis. Approved Jan 9, 2020. Taken by mouth.

More about Blueprint Medicines

Blueprint also discovered pralsetinib (Gavreto) for RET-altered cancers. Roche returned its rights in 2024, and Blueprint sold the U.S. rights to Rigel Pharmaceuticals the same year. The pipeline includes elenestinib (BLU-263), a next-generation KIT D816V inhibitor in Phase 2/3 for indolent systemic mastocytosis.

Where Blueprint Medicines trials take place

The trials above run at 200 study sites in 26 countries. Tap a country to see its states, cities and hospitals.

United States
73▼
Germany
28▼
Italy
14▼
France
13▼
United Kingdom
10▼
Belgium
8▼
Netherlands
7▼
Spain
6▼
Canada
4▼
Portugal
4▼
Sweden
4▼
Norway
3▼

Rare diseases Blueprint Medicines works on

Each disease page lists every open trial, not only Blueprint Medicines's, plus approved treatments.

Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors.

How common: About 6,000 new cases per year in the U.S. (American Cancer Society); true incidence may be higher as small GISTs are often incidentally discovered

Mastocytosis

Mastocytosis is a rare hematological disorder characterized by clonal expansion of mast cells in bone marrow, organs, and tissues.

How common: 1 in 10,000 to 1 in 300,000 (estimates vary widely)

Systemic Mastocytosis

Systemic Mastocytosis is a rare hematologic disorder characterized by accumulation and proliferation of abnormal mast cells in bone marrow, lymphoid tissues, and other organs.

How common: Approximately 1 case per 10,000 to 20,000 people; can occur at any age but more common in adults

Where to get support

Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Blueprint Medicines's own site is blueprintmedicines.com, and our help paying for treatment page lists drugmaker programs and charity funds.

Questions about Blueprint Medicines